Members of the Switch Therapeutics team (L-R): Discovery biology director Lisa Scherer, CEO Dee Datta and chief technology officer Si-ping Han
March 14, 2023 07:00 AM EDTUpdated 08:17 AM
Financing
Startups

Eli Lil­ly, UCB and oth­ers Switch in­to gear with $52M for new RNA biotech

Kyle LaHucik

Senior Reporter

South San Fran­cis­co biotech Switch Ther­a­peu­tics un­wrapped Tues­day morn­ing with $52 mil­lion to fi­nance con­di­tion­al­ly ac­ti­vat­ed siR­NA mol­e­cules.

As its name sug­gests, the start­up said …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Com­pound­ed weight loss drugs have re­sult­ed in mis­dos­ing, hos­pi­tal­iza­tions, FDA warns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times